High tumor mutational burden and neoantigen load, which are fairly common across cancer types compared with the uncommon MSI-H (248), have also been correlated with sensitivity to PD-1 blockade (higher ORR and/or prolonged survival) in melanoma, NSCLC, glioma (243, 249–252), and likely across types of solid cancers (252). This evidence concerns the gene PDCD1 and cancer.